We have been looking into other genomic markers, not presented at this conference, but potentially RB1, PTEN, PTEN loss, and TP53 mutations indicate that those patients have a poorer prognosis. Also others like spot mutations might lead to a better prognosis. And I think we should try to include those data as well as clinical factors, like high tumor burden, low PSA, in combination with a high tumor burden, like aggressive variant features, into clinical decision making...
We have been looking into other genomic markers, not presented at this conference, but potentially RB1, PTEN, PTEN loss, and TP53 mutations indicate that those patients have a poorer prognosis. Also others like spot mutations might lead to a better prognosis. And I think we should try to include those data as well as clinical factors, like high tumor burden, low PSA, in combination with a high tumor burden, like aggressive variant features, into clinical decision making. And right now, we probably most look at tumor burden, like high volume, low volume disease. But I think there’s more to come.
